Sensus lands Health Canada nod for its skin cancer system
Sensus Healthcare won Health Canada approval for its device for non-surgical skin cancer treatment, following wins in the U.S. and the U.K.
Sensus Healthcare landed Health Canada approval for its SRT-100, a therapy device designed to non-surgically treat skin cancer in hospitals and private practice settings.
The SRT-100 system features the company's SharpBeam characteristics, treating targeted lesions while leaving surrounding healthy tissue intact. The device treats non-melanoma skin cancer, providing virtually pain-free treatment according to the press release.